KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) EBIT Margin: 2009-2024

Historic EBIT Margin for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to -1.83%.

  • Teva Pharmaceutical Industries' EBIT Margin rose 2086.00% to 19.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 10.89%, marking a year-over-year increase of 802.00%. This contributed to the annual value of -1.83% for FY2024, which is 456.00% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported EBIT Margin of -1.83% as of FY2024, which was down 167.02% from 2.73% recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' EBIT Margin ranged from a high of 10.81% in FY2021 and a low of -21.44% during FY2020.
  • Its 3-year average for EBIT Margin is -4.61%, with a median of -1.83% in 2024.
  • As far as peak fluctuations go, Teva Pharmaceutical Industries' EBIT Margin skyrocketed by 3,225bps in 2021, and later crashed by 2,553bps in 2022.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' EBIT Margin stood at -21.44% in 2020, then surged by 3,225bps to 10.81% in 2021, then plummeted by 2,553bps to -14.72% in 2022, then spiked by 1,745bps to 2.73% in 2023, then slumped by 456bps to -1.83% in 2024.